Abstract
Sickle cell anemia (SCA) is one of the most prevalent genetic blood diseases in the world. Currently, therapeutic strategies aiming to increase the levels of fetal hemoglobin (HbF) contribute significantly in reducing morbidity and mortality associated with the disease. The comprehension of the molecular mechanisms involved in fetal hemoglobin gene silencing may allow the development of d…